Dr. Coleman is an entrepreneurial synthetic biologist who co-found Codagenix, Inc. to commercialize the genome design platform for vaccine development he co-invented. Dr. Coleman has oversaw the raising of $17M and securing partnerships in the agricultural vaccine space. Dr. Coleman led Codagenix’s influenza vaccine candidate from bench to bedside, where it is currently being tested in Phase I/II human trials. Dr. Coleman leads all aspects of the Codagenix business. Dr. Coleman is a skilled and creative microbiologist who has made pivotal advances in synthetic biology (Science 2008). His work possesses a unique vision and he is passionate about utilizing rational gene design to solve pertinent medical issues and emergent biothreats. Dr. Coleman holds a BS from Tulane University, a PhD from Stony Brook University, and an MBA from the New York Institute of Technology.